PARIS--(BUSINESS WIRE)--Nanobiotix, an emerging nanomedicine company, announced today that an independent preclinical study has validated the applicability of using its nanoparticles—nanoPDT—to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology.
